Ansofaxine (TP1)
Major Depressive Disorder
Key Facts
About Sumitomo Pharma
Sumitomo Pharma's mission is to translate cutting-edge science into innovative therapies that address significant unmet medical needs, particularly in psychiatry and oncology. The company has achieved global recognition through its commercialized products like Latuda® (lurasidone) and is advancing a robust pipeline of next-generation modalities. Its strategy hinges on a balanced portfolio, combining revenue-generating assets with high-risk, high-reward R&D in gene therapy and radiopharmaceuticals, supported by strategic global partnerships and internal discovery capabilities.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| NBS System for MDD | Nexstim | Approved |
| NeuroStar for MDD | Neuronetics | Approved |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Neurotyping Platform for MDD | Universal Brain | Development |